Veterinary Practice Valuation: The Complete 2026 Guide

Key takeaways

• Veterinary practice valuation in 2026 is fundamentally an EBITDA-multiple exercise. Normalized EBITDA × a multiple between 4 and 13, with the actual multiple driven by practice profile (specialty mix, multi-doctor coverage, revenue band) and — crucially — by whether buyers are competing for the deal.
• The single biggest variable in what your practice actually clears is not the valuation methodology. It is the gap between a direct single-bidder offer (where one buyer sets the price based on their internal model) and a competitive process outcome (where multiple qualified buyers compete on full deal terms).
• Online calculators are useful for orientation, not for negotiation. They can place your practice in a general range based on revenue and a rough multiple. They cannot account for the practice-specific factors that determine your actual outcome: buyer pool composition, deal structure options, specialty mix, market geography, real estate, doctor retention, brand value.
• Normalized EBITDA is the figure buyers actually multiply by. Getting normalization right — surfacing every personal-discretionary expense that should be added back, documenting it defensibly, and presenting it correctly to buyers — typically adds meaningful value over an under-normalized starting point.
• The most reliable way to know what your specific practice is worth in the 2026 market is to combine a defensible EBITDA-based valuation with a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group. The outcome of that process is consistently higher than what an offline valuation predicts, because the competitive dynamic produces leverage on terms that a static valuation cannot capture.

The valuation conversation tends to start in one of two places. The first place is “I’m getting outreach from buyers and I want to know if their number is fair before I engage.” The second place is “I’m thinking about selling in the next few years and I want to know what range I’d be in if I sold today.” Both questions are valid and the answer is roughly the same structurally — but the implications for what you do next are different.

This guide is the complete picture I’d lay out across a dinner table if a vet asked me what their practice is worth. The valuation methods that matter in 2026.

The math behind the multiples. The factors that move your specific practice up or down within the range.

The difference between a calculator estimate and a defensible value. And the relationship between any valuation number and what you actually clear at the closing table — which is rarely the same thing.

What veterinary practice valuation actually means

Before any numbers, two distinctions worth getting right.

Valuation vs. appraisal. In everyday language and in most M&A contexts, the words are used interchangeably. Technically, an appraisal is a formal written report produced by a credentialed appraiser, typically required for tax, estate, divorce, partnership-buyout, or bank-financing purposes.

A valuation is the broader process of estimating economic worth. For sale-preparation purposes, what matters is a defensible EBITDA-based value range that holds up against the buyer’s own due diligence — which a formal appraisal is not necessarily designed to produce, and which a good sell-side advisor produces as part of their standard work.

Valuation vs. price. Valuation is what your practice is worth in an abstract sense — based on financial performance, market multiples, and practice profile. Price is what a specific buyer actually pays.

The gap between valuation and price is the entire reason competitive processes exist. A practice with a “valuation” of $5 million can sell for $4 million in a direct conversation with one buyer or $6 million in a competitive process with multiple qualified buyers — same practice, same numbers, fundamentally different price because the dynamic produced different leverage.

Valuation predicts the band; competitive process determines where inside that band you actually land.

How much is your veterinary practice worth?

The honest 2026 answer for most US veterinary practices: normalized EBITDA × a multiple between 4 and 13, with the multiple driven primarily by practice profile and the actual outcome shaped heavily by whether buyers are competing for the deal.

The ranges (per industry M&A commentary from Octus, Capstone Partners, Dechert LLP, and Holland & Knight, 2025-2026):

• Single-doctor general practices under $1 million in revenue typically clear in the 4x to 7x EBITDA range. The buyer pool is concentrated in smaller PE-backed groups, regional consolidators, and individual buyers.
• Multi-doctor general practices in the $1 million to $2 million revenue range typically clear in the 6x to 9x EBITDA range when sold through a competitive process. The buyer pool widens to include mid-market PE-backed platforms.
• Strong multi-doctor general practices in the $2 million-plus revenue range typically clear in the low-teens multiple of EBITDA when sold through a competitive process. The full buyer pool — NVA, Mars-affiliated entities (VCA, BluePearl), VetCor, PetVet, Mission Pet Health, AmeriVet, Thrive, Alliance, the partnership-emphasis buyers, and others — competes for these practices.
• Specialty and emergency hospitals typically clear meaningfully higher than comparable revenue general practices. The relevant buyer pool is concentrated (BluePearl, Ethos within NVA, MedVet, regional specialty roll-ups), the operational complexity supports premium multiples, and the capital intensity (advanced equipment, specialty staff) shifts the valuation calculus.
• Larger multi-location groups ($10 million-plus revenue, $2 million-plus EBITDA) often clear at the higher end or beyond the typical ranges, with deal sizes scaling into eight-figure-plus territory.

These ranges are starting points, not endpoints. The actual multiple for a specific practice depends on the practice-specific factors covered later in this guide.

And the headline multiple is only one of several variables that determine total economic outcome — earnout structure, rollover or partnership equity terms, real estate treatment, non-compete scope, and post-sale role each have real dollar value attached.

The three valuation methods (and which actually matters)

Three valuation methodologies appear in veterinary practice contexts. They produce different answers and they answer different questions.

Income approach (EBITDA multiple method). This is the dominant method for veterinary practice M&A. The math is straightforward: normalized EBITDA × an appropriate multiple.

The multiple comes from market comparables — recent transactions involving similar practices, adjusted for the specific profile of the practice being valued. The EBITDA multiple method is what virtually every institutional buyer uses to underwrite a veterinary acquisition, which makes it the most defensible method when negotiating against a buyer’s own valuation work.

Market approach (comparable sales). This method looks at recent sales of comparable practices and back-calculates an implied value. In a transparent M&A market the market approach would be straightforward.

In veterinary M&A — where most transactions are private and most deal terms are confidential — the comparable data is thinner than it would be in a public-comp situation. The market approach in practice ends up informing the multiple used in the income approach rather than producing an independent valuation.

Asset approach (book value / liquidation). This method values the practice as the sum of its assets minus its liabilities. For most operating veterinary practices, the asset approach produces a value far below what a buyer would actually pay — because the practice’s value is in its operating cash flow and goodwill, not its balance sheet assets.

The asset approach is occasionally relevant for distressed practices, partial-asset sales, or specific tax situations. For most sale-preparation purposes, it is not the right method.

The practical implication: when a veterinary practice is sold to an institutional buyer through a competitive process in 2026, the deal is almost always priced as a multiple of normalized EBITDA. A defensible valuation focuses on getting normalized EBITDA right and selecting an appropriate multiple range — and then the competitive process determines where inside that range the deal actually lands.

EBITDA: what it captures, what it misses

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure of operating profit that strips out financing decisions (interest), tax structure choices (taxes), and accounting depreciation/amortization decisions — to produce a comparable measure of what the underlying business actually generates in operating cash flow.

For a veterinary practice, EBITDA captures: revenue minus the cost of running the practice (staff, supplies, drugs, rent, utilities, marketing, insurance, owner compensation at market rate, etc.). It does not include the owner’s actual compensation if that compensation is above or below market rate.

It does not include personal-discretionary expenses run through the practice. It does not include one-time costs (a single equipment purchase, a one-year IT overhaul, a one-time legal expense).

The figure buyers actually multiply by is normalized EBITDA — the practice’s EBITDA adjusted for these items. Getting normalization right is one of the highest-leverage parts of valuation work.

What gets added back to normalize

The standard add-back categories for a veterinary practice:

• Owner compensation above market rate. If the owner pays themselves $400K when the market rate for the work they do (clinical hours, administrative role, weekend coverage) would be $250K, the $150K differential is added back.
• Family on payroll above market rate. If a spouse, child, or family member is on payroll at compensation above what their role would command on the open market, the differential is added back.
• Personal vehicle and travel expenses. Vehicles registered through the practice, fuel, maintenance, insurance for vehicles primarily for personal use are added back.
• Personal-use real estate and home-office expenses. If the practice pays for items that primarily benefit the owner personally (home office allocations, personal real estate carrying costs), those are added back.
• Family or owner health insurance differentials. If owner-family health insurance through the practice costs more than what an employee benefit would cost, the differential is added back.
• One-time costs. Single-event expenses (a legal dispute settlement, one major equipment purchase being capitalized as expense, a one-year IT overhaul) are added back to produce a recurring-EBITDA picture.
• Below-market owner-occupied real estate. If the owner owns the practice real estate personally and the practice pays below-market rent, the rent differential is added back (because a buyer will pay market rent post-close).

What is NOT added back

• Routine staff compensation. A buyer will continue to pay the staff that runs the practice.
• Routine marketing, supplies, utilities, equipment maintenance. A buyer will continue to incur these.
• Owner compensation up to market rate. A buyer will pay a market-rate medical director and the practice needs to generate enough to support that.
• Recurring legal, accounting, professional services. A buyer will continue to need these.

The discipline of normalization is being honest about what is genuinely a personal-discretionary expense vs. what is a recurring cost of running the practice. Buyers’ diligence teams test every add-back.

An add-back that doesn’t survive diligence reduces the EBITDA the buyer underwrites — which in turn reduces the multiple-driven price.

The multiple: where does the 4x-13x range come from?

A practice’s multiple — the number that gets multiplied against normalized EBITDA — is set by a combination of practice profile, buyer pool composition, and market dynamics. The same normalized EBITDA can yield a 5x outcome in one practice profile and a 13x outcome in another.

The factors that move your multiple

Practice size. Larger practices typically command higher multiples than smaller ones, because the buyer pool deepens (more buyers can underwrite a larger deal) and operational stability tends to be greater. A multi-doctor practice with $5M revenue and $1.5M normalized EBITDA can clear at a meaningfully higher multiple than a single-doctor practice with $1M revenue and $250K normalized EBITDA — even though both are “good practices.”

Doctor count and coverage. Multi-doctor practices clear at higher multiples than single-doctor practices, primarily because key-person risk is lower. If the practice’s revenue depends heavily on one veterinarian, a buyer needs to underwrite that doctor staying for a meaningful post-close period (medical director arrangement, earnout) — and the price reflects that conditional value.

A practice with three or four DVMs where no single doctor drives more than 35% of clinical revenue has significantly less key-person risk and clears higher.

Specialty mix. Specialty services (advanced surgery, internal medicine, dermatology, oncology, neurology, ophthalmology, dentistry, behavior, emergency, critical care) command higher multiples than general practice. Specialty buyers (BluePearl, Ethos within NVA, MedVet, regional specialty roll-ups) compete for these platforms, and the operational complexity supports premium pricing.

A multi-doctor general practice with a meaningful specialty referral component typically clears higher than a pure GP of similar size.

EBITDA margin. Practices operating at higher EBITDA margins (operating profit as a percentage of revenue) typically clear at higher multiples within their revenue band. A $3M practice operating at 25% normalized margin (so $750K EBITDA) often clears at a higher multiple than a $3M practice operating at 15% normalized margin (so $450K EBITDA) — partly because the higher-margin practice signals operational quality and partly because the dollar EBITDA is larger, attracting a wider buyer pool.

Growth trajectory. Practices with documented top-line growth across the trailing 24-36 months clear at higher multiples than flat or declining practices. Growth signals operational momentum and supports the buyer’s underwriting of future cash flow.

The growth needs to be organic (not just acquisition-driven) and demonstrably continuing — a one-year spike followed by flatness reads as noise, not trajectory.

Market geography. Practices in growing markets (Sun Belt, suburbanizing metros, retirement-demographic regions) typically clear at higher multiples than practices in declining markets. The buyer’s underwriting includes a view on the local market’s pet-owning population trajectory, household-income trajectory, and competitive landscape.

Practices in markets with positive demographic trends benefit on the multiple side.

Real estate. Practices that own their real estate and can include it in the sale (or structure a clean lease-back arrangement) typically clear at higher total deal value than practices that rent from a third-party landlord on a short remaining lease term. The real estate dimension affects both the deal value and the deal structure.

Equipment and infrastructure. Practices with modern, well-maintained equipment, digital records, and operational systems clear at higher multiples than practices with aging infrastructure, paper records, or operational complexity that a buyer would need to invest capital to fix.

Doctor retention probability. A practice where the selling owner and associate doctors are committed to staying through a medical director arrangement (typically 3 to 5 years) clears at a higher multiple than a practice where doctor retention is uncertain. The retention question is at the center of every buyer’s underwriting.

Brand and patient retention. Practices with strong local brand recognition, long average patient tenure, and demonstrated client retention through staff changes clear at higher multiples than practices with high client churn or brand dependence on a specific doctor.

Buyer pool depth and competition. This is the variable that moves the multiple most dramatically. A practice that fits the criteria of one institutional buyer can be sold at the lower end of its band in a direct conversation with that buyer.

The same practice, invited into a structured competitive process with five or six qualified institutional bidders, often clears at the upper end of its band — sometimes meaningfully above it.

The valuation calculator approach (and its limits)

Online veterinary practice valuation calculators are useful for orientation. They are not adequate for decision-making when you are seriously evaluating a sale.

What a calculator does well. A calculator can take revenue, rough margin, doctor count, and location, and produce a rough EBITDA-multiple range. That range is useful for: deciding whether to engage with a buyer who has reached out, understanding the general band your practice falls into, and starting the mental modeling around your post-sale financial picture.

The calculator’s range will typically be reasonable as a starting point — somewhere in the band you’d actually land.

What a calculator cannot do. The calculator cannot model the practice-specific factors that determine where inside the band you actually land. It cannot evaluate buyer-pool composition for your specific practice.

It cannot account for deal-structure options (cash at close vs. earnout vs. rollover or partnership equity) that have real dollar implications. It cannot model what a competitive process would produce vs. a direct conversation.

It cannot incorporate real estate considerations, specialty premium adjustments, doctor-retention probability, or market-geography effects with the specificity that an experienced advisor brings.

The practical implication. Use a calculator to get oriented. Engage a sell-side advisor to get a defensible valuation.

The advisor’s valuation will incorporate the practice-specific factors and produce a range that holds up at the negotiating table. The calculator’s range is a starting point for the conversation; the advisor’s valuation is the basis for the negotiation.

How to prepare your practice for a defensible valuation

Three preparation horizons matter, depending on how soon you might sell.

12 to 24 months out — strategic value-building. The highest-leverage value-building moves take time. Develop associate doctors to reduce key-person concentration.

Build out a specialty referral component if it fits your market. Document operational systems and protocols.

Clean up financial records. Address real estate ownership questions.

These moves can compound across 18-24 months in ways that meaningfully shift your sale value.

6 to 12 months out — tactical preparation. Engage your sell-side advisor. Begin the financial-document preparation work.

Normalize EBITDA defensibly with the advisor’s analytical support. Address any operational issues that would surface in due diligence.

Begin thinking about post-sale role, non-compete scope, and the deal terms you want. This is the window where the actual sale process becomes concrete.

3 to 6 months out — final preparation and process launch. Final financial documentation and EBITDA normalization. Buyer-pool curation.

Investment memo and process materials. The actual competitive process opens 3 to 4 months before the target close date, with bidder invitations going out, diligence access provided, and bids returning across a defined window.

What TE does in this preparation work

Our pre-sale financial review is a thorough analysis of the practice’s last 24-36 months of P&Ls, normalizing EBITDA defensibly, identifying every add-back category that genuinely belongs in the calculation, and documenting each add-back with the supporting records buyers will want to see. We do this on our side of the table — the seller doesn’t need to commission a separate Quality of Earnings audit themselves; that’s part of what we provide.

The output is a defensible normalized EBITDA figure and an EBITDA-multiple range tailored to the practice’s specific profile and the buyer pool that would compete for it.

The work is detailed and analytically rigorous. It produces a number — and just as important, it produces the documentation that supports the number when the buyer’s diligence team starts asking questions.

The relationship between valuation and what you actually clear

A defensible valuation tells you the band your practice should land in. The competitive process determines where inside that band you actually clear — and how much beyond the band the upside extends.

The mechanical reason: without competition, a buyer has no structural pressure to bid against their own internal valuation ceiling. They can offer the lower end of the band as a credible-sounding number and expect a single seller without alternatives to engage with it.

With competition, every buyer in the room knows other qualified bidders are underwriting the same practice. Each bidder must put their best terms forward in the bidding window — not just on the headline multiple but on the entire deal structure (cash percentage, earnout protections, rollover or partnership equity terms, non-compete scope, post-sale role, brand handling, integration roadmap).

The result that holds across deal types and practice profiles: the gap between a direct single-bidder offer and a competitive winning bid in our process has consistently run into seven-figure territory on practices in the qualifying revenue band ($2M+). On larger multi-location practices, the gap routinely exceeds that.

The valuation tells you the starting band; the competitive process delivers the actual outcome.

Want to know what your practice is worth in the 2026 market? Get a Free Practice Value Estimate — send us your last 12 months of P&L and basic practice details. We’ll normalize the EBITDA properly, identify the right buyer pool, and send you back a defensible value range with the math behind it. No upfront cost, no obligation.

Common valuation mistakes to avoid

Six patterns we see consistently when practices are valued by owners working without experienced sell-side support.

Under-normalizing EBITDA. The most common mistake. Owners often miss legitimate add-backs (vehicle expenses, family compensation differentials, one-time costs) that should be in the calculation.

An under-normalized EBITDA produces a lower starting figure, which multiplies through to a lower price. Documenting add-backs defensibly is one of the highest-leverage parts of preparation.

Confusing revenue with value. A $3M practice does not have a $3M sale value. A practice’s value comes from its operating cash flow — its EBITDA — multiplied by an appropriate multiple.

Two practices with the same revenue but different margins clear at very different prices.

Anchoring on a single buyer’s offer. The number a single buyer offers in a direct conversation reflects what that buyer perceives the seller will accept without competitive pressure. That number is rarely the same as the competitive-process outcome.

Treating a single buyer’s offer as the valuation undersells the practice.

Using outdated comparables. Multiples shift with market cycle. The 2020-2021 peak multiples for veterinary practices were materially higher than the 2023 trough multiples.

The 2025-2026 market has recovered and stabilized but not to 2021 levels. Using 2021-era comparables today overstates value; using 2023-era comparables today understates it.

Ignoring deal structure. The headline multiple is only one component of total economic outcome. Cash at close percentage, earnout structure and protections, rollover or partnership equity terms, non-compete scope, post-sale role — each has real dollar value.

A 10x multiple with 60% cash at close and weak earnout protections can produce less actual money in the seller’s pocket than a 9x multiple with 80% cash at close and strong earnout protections.

Skipping the competitive process. The single most consequential valuation-related mistake. A defensible valuation establishes the band; a structured competitive process determines the outcome inside the band.

Owners who accept the first offer they receive — even if the number looks reasonable against a calculator — are leaving money on the table that a structured process consistently surfaces.

When to get a professional valuation

The decision points where a professional valuation matters most:

• You are considering selling within the next 24 months. A professional valuation now establishes the baseline, identifies the gap between current value and target value, and frames the strategic moves available to close that gap.
• A buyer has reached out with a direct offer. A professional valuation tells you whether the offer is in the right band, identifies where the offer can be pushed, and frames the competitive-process alternative.
• You are evaluating bringing in a partner or associate buy-in. A professional valuation establishes a defensible basis for the buy-in pricing and equity allocation.
• You are doing succession planning or estate planning. A formal appraisal may be required for tax or estate purposes. The professional valuation work can extend into a formal appraisal if needed.
• You are unsure whether selling makes sense for your situation. A professional valuation produces the financial picture needed to evaluate the decision against your post-sale lifestyle, retirement timing, and financial goals.

For each of these, the value of professional involvement is not the number alone — it is the documentation, the analytical framework, and the buyer-pool intelligence that surrounds the number. A defensible value range is useful; the underlying preparation makes the actual sale process meaningfully better.

How TE approaches valuation for the practices we represent

Our Free Practice Value Estimate is the entry point. The seller sends us 12 months of P&L and basic practice details.

We normalize the EBITDA properly, identify the right buyer pool for the practice’s profile, and send back a defensible value range with the math behind it. The estimate is free, has no upfront cost, and creates no obligation.

If the seller decides to engage TE for the sale process, the valuation work deepens. We pull the full trailing 24-36 months of financials.

We document every add-back defensively with the supporting records. We build the investment memo that qualified bidders will use to underwrite the deal.

We curate the buyer pool — only buyers that fit the specific practice profile get invited inside the competitive process. We run the structured bidding window.

We compare the resulting offers term-by-term.

The total economic outcome consistently exceeds what an offline valuation predicts. The competitive process is the lever that bridges the valuation to the actual sale price.

The 2026 valuation environment

Two contextual factors worth understanding about the 2026 market specifically.

The capital environment. Private equity dry powder available for veterinary services investments has been at historically elevated levels through 2025-2026. JAB Holdings‘ continued long-hold posture at NVA, Ares Management at PetVet, Shore Capital at Mission Pet Health, AEA + Oaktree at AmeriVet, Harvest Partners at VetCor, L Catterton at Alliance, TSG Consumer Partners at Thrive — every major sponsor has active deployment capacity.

The capital availability supports active bidding and competitive deal pricing for practices that fit institutional criteria.

The acquisition cadence. Per Capstone Partners‘ April 2026 Pet Sector M&A Update, deal volume accelerated meaningfully entering Q1 2026 versus the same window in 2025. Both PE-backed roll-ups and strategic acquirers are running active pipelines.

The acceleration reflects the broader recovery from the 2023 deal-volume trough plus the maturation of institutional platforms with refined operational infrastructure ready to integrate additional acquisitions.

The practical implication for owners: 2026 is a constructive market environment for selling. The multiples are not at 2021 peak levels and probably will not return to those levels in this cycle, but the current environment is meaningfully better than the 2023 trough — and the buyer-pool competition for practices in the $2M-plus revenue band is robust.

Closing thought

Veterinary practice valuation in 2026 is fundamentally a structured exercise: normalize EBITDA properly, select an appropriate multiple range from market comparables, factor in the practice-specific variables that move you within that range. Every institutional buyer in the market uses essentially this framework when they underwrite an acquisition.

A defensible valuation puts you on the same analytical footing as the buyer’s diligence team.

But the valuation is the starting line, not the finish line. What your practice actually clears depends on whether you bring buyers into competition for the deal — and on the practice-specific work done in the preparation window before the process opens.

The combination of a defensible valuation and a structured competitive process consistently delivers outcomes that exceed what either alone can produce.

If you have a buyer’s offer in hand or you are within the next 24 months of a potential sale, the highest-leverage move is to get a defensible value range for your specific practice before you commit to any particular path. Get a Free Practice Value Estimate and we’ll send you the same value range we would produce for a client across a dinner table — with the math that supports it.

Sources

Industry M&A research and valuation data

1. Capstone Partners. Pet Sector M&A Update — April 2026. Capstone Partners industry research.
2. Octus. Veterinary Services Roll-Up Coverage, 2025-2026. Octus credit research and industry commentary.
3. Dechert LLP. Healthcare M&A: 2025-2026 Trends and Outlook. Dechert healthcare practice publications.
4. Holland & Knight. Healthcare Private Equity 2025-2026 Commentary. Holland & Knight healthcare practice publications.
5. MB Law Firm. 2025 Healthcare M&A Trends — Joint Venture and Partnership Structures. MB Law Firm healthcare publications.

Veterinary industry economic data

6. iVET360. State of the Veterinary Industry — 2026 Industry Report. iVET360 industry research.
7. American Veterinary Medical Association (AVMA). 2026 AVMA Veterinary Economic Report. AVMA economic research.

TE buyer-pool reference

8. Transitions Elite. Veterinary practice consolidator directory. 42 verified consolidators with active US acquisition activity.
9. Transitions Elite. How much private equity is paying for veterinary practices. Detailed PE-backed buyer pricing analysis.
10. Transitions Elite. EBITDA benchmarks in vet practice sales. Detailed EBITDA multiple data by practice profile.